Sign In
Buy AQST
$4.03
+0.100 (+2.54%)
At Close: Jun 03, 2026
INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
05:03pm, Monday, 12'th Jan 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Aquestive Therapeutics To Contact Him Directly To Discuss Their Options I
Down 37% in 4 Weeks, Here's Why Aquestive Therapeutics (AQST) Looks Ripe for a Turnaround
10:36am, Monday, 12'th Jan 2026
Aquestive Therapeutics (AQST) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earni
Benzinga Bulls And Bears: Chevron, Palantir, Aquestive — And Real Estate Stocks Plummet
08:31am, Saturday, 10'th Jan 2026
Benzinga examined the prospects for many investors' favorite stocks over the last week - here's a look at some of our top stories.
INVESTOR ALERT: Investigation of Aquestive Therapeutics, Inc. (AQST) by Holzer & Holzer, LLC
02:11pm, Friday, 09'th Jan 2026
ATLANTA, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST) complied with federal securi
Bad News For Competitor Turns Into Big Win For ARS Pharma Stock
12:32pm, Friday, 09'th Jan 2026
ARS Pharmaceuticals Inc. (NASDAQ: SPRY) stock rose Friday in reaction to a negative update for its rival Aquestive Therapeutics Inc. (NASDAQ: AQST).
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics
11:49am, Friday, 09'th Jan 2026
NEW YORK--(BUSINESS WIRE)---- $AQST #AQST--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. (“Aquestive” or the
Aquestive Stock Slides After FDA Flags Issues With Allergy Drug Application
11:28am, Friday, 09'th Jan 2026
Aquestive Therapeutics Inc. (NASDAQ: AQST) stock is trading lower on Friday, with a session volume of 5.68 million compared to the average volume of 2.79 million, as per data from Benzinga Pro.
Block & Leviton is investigating Aquestive Therapeutics (Nasdaq: AQST) for possible securities fraud. Investors who lost money should contact the firm.
WARREN, N.J., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement
Aquestive Therapeutics: Looking For The PDUFA Run-Up
04:21am, Friday, 09'th Jan 2026
Aquestive Therapeutics is positioned for a potential PDUFA run-up ahead of Anaphylm's FDA decision on January 31, 2026. Anaphylm's needle-free, oral epinephrine alternative could capture 8-12% of the
Aquestive Therapeutics (AQST) Upgraded to Buy: Here's Why
01:01pm, Wednesday, 07'th Jan 2026
Aquestive Therapeutics (AQST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Jim Cramer: Joby Is 'Losing Too Much Money'
08:00am, Wednesday, 12'th Nov 2025
On CNBC's “Mad Money Lightning Round,” Jim Cramer said Aquestive Therapeutics, Inc. (NASDAQ:AQST) is a “very interesting spec.”
Aquestive Therapeutics, Inc. ( AQST ) Discusses Anaphylm Regulatory Progress, Commercial Strategy, and Pipeline Development November 6, 2025 12:00 PM EST Company Participants Daniel Barber - CEO, Pres
Aquestive Therapeutics, Inc. (AQST) Q3 2025 Earnings Call Transcript
12:36pm, Thursday, 06'th Nov 2025
Aquestive Therapeutics, Inc. ( AQST ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Daniel Barber - CEO, President & Director Ernie Toth - Chief Financial Officer Sherry Korc
Here's What Key Metrics Tell Us About Aquestive Therapeutics (AQST) Q3 Earnings
07:01pm, Wednesday, 05'th Nov 2025
Although the revenue and EPS for Aquestive Therapeutics (AQST) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compar
